NCT02389413CompletedPhase 2
A Phase 2A Multicentre, Randomised, Double Blind, Placebo-Controlled, Parallel-Group Safety and Tolerability Study of PQ912 in Subjects With Early Alzheimer's Disease
Vivoryon Therapeutics N.V.23 sites in 7 countries120 target enrollmentStarted: March 2015Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Vivoryon Therapeutics N.V.
- Enrollment
- 120
- Locations
- 23
- Primary Endpoint
- Frequency of adverse events and serious adverse events (the study is a Phase II safety trial)
Study Overview
Brief Summary
The aim of this study is to evaluate the safety, tolerability and preliminary efficacy of PQ912 in subjects with Mild Cognitive Impairment (MCI) due to Alzheimers Disease (AD) or mild dementia due to AD.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 50 Years to 89 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Signed and dated written informed consent
- •Male or surgically sterile or postmenopausal female aged ≥ 50 to ≤ 89 years. Male subjects with childbearing potential partners are willing to and should use condoms during treatment and until 28 days of the last dose of study medication.
- •Diagnosis of MCI due to AD or mild dementia due to AD with amnestic presentation, according to AA-NIA (Alzheimer's Association (AA) and the National Institute on (Aging NIA) criteria [Albert et al 2011; McKhann et al 2011]
- •Mini-Mental State Examination (MMSE) score of 21 to 30 inclusive at screening
- •A positive AD signature showing one of the following (either a, b, c, OR d):
- •Screening CSF sample with an A-beta 42 concentration of less than 638 ng/L AND total tau >375 ng/L, as assessed by central laboratory.
- •Screening CSF sample with an A-beta 42 concentration of less than 638 ng/L AND p-tau > 52 ng/L, as assessed by central laboratory.
- •Tau/A-beta ratio > 0.52, as assessed by central laboratory.
- •A positive amyloid PET if available prior to screening.
- •Treatment naïve, this means not having received any prior established specific treatment for MCI due to AD or mild dementia due to AD including no (prior) use of an acetylcholinesterase inhibitor or memantine. A maximum of two months of prior cumulative treatment with an acetylcholinesterase inhibitor or memantine is allowed if the acetylcholinesterase inhibitor or memantine was discontinued due to intolerance, and if this was done at least two months prior to baseline. Use of Souvenaid will be allowed if Souvenaid was discontinued at least twomonths prior to baseline, or if the subject is on stable dose for at least six months prior to baseline and is willing to continue during the study on the same dose and frequency.
- •Outpatient with study partner capable of accompanying the subject on all clinic visits. In accordance to Swedish regulations availability of study partner is not applicable for Sweden.
Exclusion Criteria
- •Significant neurologic disease, other than AD, that may affect cognition.
- •Atypical clinical presentations of MCI due to AD or mild dementia due to AD, such as the visual variant of AD (including posterior cortical atrophy) or the language variant (including logopenic aphasia).
- •Concomitant disorders:
- •Severe hepatic (Child-Pugh C) and/or kidney failure (creatinine clearance (estimated Glomerular Filtration Rate - eGFR) ≤ 30 ml/min/1.73m2) and/or serum creatinine above 1.5 fold of Upper Limit Normal (ULN) and/or Alanine-Amino Transferase (AST) or Asparagine-Amino Transferase (ALT) above 3 fold ULN at baseline.
- •History of or screening visit brain MRI scan indicative of any other significant abnormality.
- •Current presence of a clinically important major psychiatric disorder (e.g. major depressive disorder) as defined by DSM-5 criteria, or symptom(s) (e.g. hallucinations) that could affect the subject's ability to complete the study.
- •. Current clinically important systemic illness that is likely to result in clinically relevant deterioration of the subject's condition or might affect the subject's safety during the study.
- •Other clinically important diseases or conditions or abnormalities of vital signs, physical examination, neurologic examination, laboratory results, or electrocardiogram (ECG) examination (e.g. atrial fibrillation) that could compromise the study or the safety of the subject.
- •Clinically important infection within 30 days prior to screening e.g. chronic persistent or acute infection, such as bronchitis or urinary tract infection.
- •Any known hypersensitivity to any of the excipients contained in the test article formulation.
- •Severe hepatic failure (Child-Pugh C) OR kidney failure (creatinine clearance (eGFR) ≤ 30 ml/min/1.73m2) OR serum creatinine above 1.5 fold of ULN OR AST or ALT above 3 fold of ULN at screening.´
- •Concomitant Medication/Therapies:
- •The following therapies are not permitted for the given intervals prior to baseline and until End-of-treatment (EOT):
- •Use of experimental medications for AD or any other investigational medications or devices for treatment of indications other than AD within 60 days prior to baseline.
- •Treatment with Souvenaid, except if the use of Souvenaid was discontinued at least two months prior to baseline, or if the subject is on stable dose for at least six months prior to baseline and is willing to continue the use of Souvenaid during the study on the same dose and frequency.
- •Concomitant treatment with St. John's Wort (a wash out phase of at least two weeks prior to baseline is required).
- •Any concomitant treatment which impairs cognitive function and cannot be washed out at least four weeks prior to baseline.
Arms & Interventions
PQ912 oral
Experimental
PQ912 will be administered orally twice daily for 12 weeks.
Intervention: PQ912 oral (Drug)
Placebo
Placebo Comparator
Placebo will be administered orally twice daily for 12 weeks.
Intervention: Placebo (Other)
Outcomes
Primary Outcomes
Frequency of adverse events and serious adverse events (the study is a Phase II safety trial)
Time Frame: 12 weeks
Secondary Outcomes
- Change from baseline in functional connectivity and network Analysis in electroencephalography (EEG)(12 weeks)
- Exploratory clinical measures (measured by a questionnaire)(12 weeks)
- Change from baseline of a panel of concept and AD-related biomarkers in Cerebrospinal fluid (CSF) (measured by Analysis of several biochemical assays)(12 weeks)
- Change from baseline in brain functional connectivity (measured by Magnetic Resonance Imaging (MRI) analysis)(12 weeks)
Investigators
Study Sites (23)
Loading locations...
Similar Trials
Terminated
Phase 2
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)Cognitive Impairment Associated With Schizophrenia (CIAS)NCT02855411Biogen35
Completed
Phase 2
A Study of RVT-1401 in Myasthenia Gravis (MG) PatientsMyasthenia GravisNCT03863080Immunovant Sciences GmbH17
Recruiting
Phase 1
The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal TumorsGastroesophageal Junction (GEJ) AdenocarcinomaNCT05964543QureBio Ltd.72
Not yet recruiting
Phase 2
Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid TumorsAdvanced Solid TumorNCT06446388Qilu Pharmaceutical Co., Ltd.360
Completed
Phase 3
A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.Chronic Obstructive Pulmonary Disease (COPD)NCT01727141Novartis Pharmaceuticals1,042